A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, ...
Despite the recent downturn, Hims & Hers Health's stock had seen a significant increase of 43% in the past five days prior to the FDA's announcement. The end of the drug shortage and subsequent ...
Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
(Reuters) - A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has ...